Cyclosporin may leads to higher complete remission of proteinuria compared with different comparators (low certainty).
Cyclosporin showed no clear difference in partial remission of proteinuria compared with different comparators (low certainty).
Cyclosporin may leads to higher complete or partial remission compared with different comparators (low certainty).
Cyclosporin showed no clear difference in chronic kidney disease compared with different comparators (low certainty).
Cyclosporin showed no clear difference in kidney failure compared with different comparators (low certainty).
Cyclosporin may leads to higher complete remission: all renal pathologies compared with placebo or no treatment (low certainty).
Cyclosporin showed no clear difference in complete remission: FSGS compared with placebo or no treatment (low certainty).
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin may leads to higher complete or partial remission: all renal pathologies compared with placebo or no treatment (low certainty).
Cyclosporin showed no clear difference in complete or partial remission: FSGS compared with placebo or no treatment (low certainty).
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
It is very uncertain whether cyclosporin changes adverse events: infection compared with placebo or no treatment (very low certainty).